Dogged by safe­ty is­sues, Eli Lil­ly and Pfiz­er tout their lat­est PhI­II for an­ti-NGF pain drug tanezum­ab

Sci­en­tists at Eli Lil­ly and Pfiz­er have racked up a fresh set of pos­i­tive ef­fi­ca­cy num­bers for their close­ly-watched an­ti-NGF pain drug tanezum­ab. But once again they have been dogged by safe­ty is­sues that have blight­ed the class.

The re­searchers not­ed that the high 10 mg dose of tanezum­ab scored a sta­tis­ti­cal­ly sig­nif­i­cant win on chron­ic low­er back pain, while the 5 mg dose fell short of the bar. We don’t know how well the top dose group per­formed though, as the team is hold­ing back the da­ta set for a con­fer­ence.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER